Laboratory Co. of America Holdings (NYSE:LH) Shares Acquired by OneDigital Investment Advisors LLC

OneDigital Investment Advisors LLC grew its stake in Laboratory Co. of America Holdings (NYSE:LH - Free Report) by 115.7% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 6,088 shares of the medical research company's stock after purchasing an additional 3,265 shares during the quarter. OneDigital Investment Advisors LLC's holdings in Laboratory Co. of America were worth $1,361,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in LH. Avantax Advisory Services Inc. boosted its holdings in Laboratory Co. of America by 5.9% in the first quarter. Avantax Advisory Services Inc. now owns 1,729 shares of the medical research company's stock worth $378,000 after acquiring an additional 97 shares in the last quarter. O Shaughnessy Asset Management LLC increased its position in shares of Laboratory Co. of America by 4.3% during the first quarter. O Shaughnessy Asset Management LLC now owns 4,890 shares of the medical research company's stock valued at $1,068,000 after acquiring an additional 203 shares in the last quarter. Seven Eight Capital LP purchased a new position in Laboratory Co. of America in the 1st quarter worth approximately $1,293,000. CANADA LIFE ASSURANCE Co boosted its stake in Laboratory Co. of America by 18.9% during the 1st quarter. CANADA LIFE ASSURANCE Co now owns 150,046 shares of the medical research company's stock valued at $32,802,000 after purchasing an additional 23,860 shares during the last quarter. Finally, MQS Management LLC increased its holdings in shares of Laboratory Co. of America by 28.1% in the 1st quarter. MQS Management LLC now owns 3,477 shares of the medical research company's stock worth $760,000 after purchasing an additional 763 shares in the last quarter. Institutional investors own 95.94% of the company's stock.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on LH. Jefferies Financial Group boosted their price objective on shares of Laboratory Co. of America from $245.00 to $265.00 and gave the company a "buy" rating in a report on Monday, September 23rd. UBS Group boosted their target price on shares of Laboratory Co. of America from $260.00 to $270.00 and gave the company a "buy" rating in a research report on Friday, August 2nd. HSBC raised shares of Laboratory Co. of America from a "hold" rating to a "buy" rating in a report on Wednesday, October 30th. Barclays lifted their price target on shares of Laboratory Co. of America from $234.00 to $249.00 and gave the stock an "equal weight" rating in a research note on Friday, October 25th. Finally, Robert W. Baird upped their price objective on Laboratory Co. of America from $282.00 to $289.00 and gave the stock an "outperform" rating in a research note on Friday, October 25th. Five analysts have rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $255.92.

Laboratory Co. of America Price Performance

Shares of NYSE:LH traded down $2.47 during midday trading on Tuesday, reaching $236.17. 584,259 shares of the company were exchanged, compared to its average volume of 673,731. The company has a current ratio of 1.44, a quick ratio of 1.30 and a debt-to-equity ratio of 0.66. The stock has a market cap of $19.75 billion, a PE ratio of 45.47, a price-to-earnings-growth ratio of 1.93 and a beta of 1.05. The business's fifty day moving average is $224.64 and its two-hundred day moving average is $216.10. Laboratory Co. of America Holdings has a one year low of $191.97 and a one year high of $247.99.

Laboratory Co. of America (NYSE:LH - Get Free Report) last issued its earnings results on Thursday, October 24th. The medical research company reported $3.50 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.48 by $0.02. The firm had revenue of $3.28 billion for the quarter, compared to analysts' expectations of $3.26 billion. Laboratory Co. of America had a return on equity of 15.27% and a net margin of 3.43%. The business's revenue was up 7.4% compared to the same quarter last year. During the same period in the previous year, the firm posted $3.38 earnings per share. As a group, analysts predict that Laboratory Co. of America Holdings will post 14.53 earnings per share for the current year.

Laboratory Co. of America Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, December 13th. Stockholders of record on Tuesday, November 26th will be issued a $0.72 dividend. This represents a $2.88 dividend on an annualized basis and a dividend yield of 1.22%. The ex-dividend date of this dividend is Tuesday, November 26th. Laboratory Co. of America's dividend payout ratio (DPR) is 55.71%.

Insider Activity

In other news, CEO Adam H. Schechter sold 6,189 shares of the stock in a transaction that occurred on Monday, November 11th. The stock was sold at an average price of $243.47, for a total value of $1,506,835.83. Following the sale, the chief executive officer now directly owns 87,441 shares in the company, valued at approximately $21,289,260.27. This represents a 6.61 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Kerrii B. Anderson sold 1,000 shares of the stock in a transaction on Thursday, October 24th. The stock was sold at an average price of $230.00, for a total value of $230,000.00. Following the completion of the sale, the director now owns 13,722 shares in the company, valued at approximately $3,156,060. The trade was a 6.79 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 0.85% of the company's stock.

Laboratory Co. of America Profile

Labcorp Holdings Inc provides laboratory services. It operates through two segments, Diagnostics Laboratories and Biopharma Laboratory Services. The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid, PAP, hemoglobin A1C and vitamin D, prostate-specific antigens, sexually transmitted diseases, hepatitis C, microbiology cultures and procedures, and alcohol and other substance-abuse tests.